CardioDx, Inc., a pioneer in the field of cardiovascular genomic diagnostics, today announced online publication of a study in the The paper, titled “A Gender Specific Blood-Based Gene Expression ...
PALO ALTO, CA--(Marketwired - Mar 10, 2014) - CardioDx, Inc., a molecular diagnostics company specializing in cardiovascular genomics, today announced the publication of the IMPACT-PCP (Investigation ...
Please provide your email address to receive an email when new articles are posted on . A low score on a blood test that evaluates age, sex and gene expression may help to rule out the presence of ...
The true incidence of obstructive coronary artery disease (CAD) among patients undergoing transcatheter aortic valve implantation (TAVI) is not known Assessment of CAD using angiography only can ...
CardioDx Also Separately Raises $20 Million in New Financing to Support the Company's Commercial Growth and Operations CardioDx, Inc., a molecular diagnostics company specializing in cardiovascular ...
Researchers have completed an observational validation study of a new genomic test for obstructive coronary artery disease for patients presenting with stable chest pain, but will release results ...
WASHINGTON, DC—Coronary CT angiography (CCTA) seems to have the edge over functional testing for the assessment of suspected CAD in patients with newly diagnosed type 2 diabetes, real-world data show.
Quest Diagnostics Inc.DGX recently entered into a national specimen-draw agreement with CardioDx, Inc., a molecular diagnostics company specializing in cardiovascular genomics. Per the agreement, both ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results